COMPANY / PUBLIC SOURCE RECORD
NordicRWE AS
NORDICRWE AS is listed at Universitetsgata 2, 0164 Oslo, Norway; website: https://nordicrwe.com/. It describes itself as an R&D-focused, technology-driven company delivering solutions for data-driven drug development. Listed industry: Health and life science.
Company news and case studies:
- “Comparative effectiveness of first line pembrolizumab vs. chemotherapy in aNSCLC: A Norwegian population-based cohort study” — https://doi.org/10.1002/cpt.3591.
- “Comparative effectiveness of atezolizumab, nivolumab and pembrolizumab in second line treatment of advanced non-small cell lung cancer” — https://authorea.com/users/803876/articles/1191557-comparative-effectiveness-of-atezolizumab-nivolumab-and-pembrolizumab-in-second-line-treatment-of-advanced-non-small-cell-lung-cancer.
- “Synthetic data as external control arms in scarce single-arm clinical trials” — https://doi.org/10.1371/journal.pdig.0000581.
Related solution: “NordicRWE: Unleashing the power of Nordic health data to bring life-changing therapies to patients faster” — https://businessnorway.com/solutions/nordicrwe-unleashing-the-power-of-nordic-health-data.
Public contact: Christian Jonasson, Research Director; cj@nordicrwe.com; +47 909 36 941.